🚀 VC round data is live in beta, check it out!
Verastem Valuation Multiples
Discover revenue and EBITDA valuation multiples for Verastem and similar public comparables like Blau Farmacêutica, 2seventy bio, Synmosa Biopharma, Eikon Therapeutics and more.
Verastem Overview
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Founded
2010
HQ
Employees
80
Website
Sectors
Financials (LTM)
EV
$364M
Verastem Financials
Verastem reported last 12-month revenue of $55M.
In the same LTM period, Verastem generated $45M in gross profit and had net loss of ($193M).
Revenue (LTM)
Verastem P&L
In the most recent fiscal year, Verastem reported revenue of $31M and EBITDA of ($208M).
Verastem expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $55M | XXX | $31M | XXX | XXX | XXX |
| Gross Profit | $45M | XXX | $26M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($208M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (672%) | XXX | XXX | XXX |
| EBIT Margin | (303%) | XXX | (550%) | XXX | XXX | XXX |
| Net Profit | ($193M) | XXX | ($209M) | XXX | XXX | XXX |
| Net Margin | (354%) | XXX | (678%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Verastem Stock Performance
Verastem has current market cap of $491M, and enterprise value of $364M.
Market Cap Evolution
Verastem's stock price is $5.59.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $364M | $491M | 2.5% | XXX | XXX | XXX | $-2.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVerastem Valuation Multiples
Verastem trades at 6.7x EV/Revenue multiple, and (1.8x) EV/EBITDA.
EV / Revenue (LTM)
Verastem Financial Valuation Multiples
As of April 11, 2026, Verastem has market cap of $491M and EV of $364M.
Equity research analysts estimate Verastem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Verastem has a P/E ratio of (2.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $491M | XXX | $491M | XXX | XXX | XXX |
| EV (current) | $364M | XXX | $364M | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | 11.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.8x) | XXX | XXX | XXX |
| EV/EBIT | (2.2x) | XXX | (2.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | 14.2x | XXX | XXX | XXX |
| P/E | (2.5x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Verastem Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Verastem Margins & Growth Rates
Verastem's revenue in the last 12 month grew by 157%.
Verastem's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $2.4M for the same period.
Verastem Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 157% | XXX | 279% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (672%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 164% | XXX | 262% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 225% | XXX | 371% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 633% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verastem Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Blau Farmacêutica | XXX | XXX | XXX | XXX | XXX | XXX |
| 2seventy bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Synmosa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eikon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Replimune Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verastem M&A Activity
Verastem acquired XXX companies to date.
Last acquisition by Verastem was on XXXXXXXX, XXXXX. Verastem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Verastem
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVerastem Investment Activity
Verastem invested in XXX companies to date.
Verastem made its latest investment on XXXXXXXX, XXXXX. Verastem invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Verastem
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Verastem
| When was Verastem founded? | Verastem was founded in 2010. |
| Where is Verastem headquartered? | Verastem is headquartered in United States. |
| How many employees does Verastem have? | As of today, Verastem has over 80 employees. |
| Who is the CEO of Verastem? | Verastem's CEO is Daniel Paterson. |
| Is Verastem publicly listed? | Yes, Verastem is a public company listed on Nasdaq. |
| What is the stock symbol of Verastem? | Verastem trades under VSTM ticker. |
| When did Verastem go public? | Verastem went public in 2012. |
| Who are competitors of Verastem? | Verastem main competitors are Blau Farmacêutica, 2seventy bio, Synmosa Biopharma, Eikon Therapeutics. |
| What is the current market cap of Verastem? | Verastem's current market cap is $491M. |
| What is the current revenue of Verastem? | Verastem's last 12 months revenue is $55M. |
| What is the current revenue growth of Verastem? | Verastem revenue growth (NTM/LTM) is 157%. |
| What is the current EV/Revenue multiple of Verastem? | Current revenue multiple of Verastem is 6.7x. |
| Is Verastem profitable? | No, Verastem is not profitable. |
| What is the current net income of Verastem? | Verastem's last 12 months net income is ($193M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.